Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration;Respiratorische insuffizienz und pulmonale fibrose als spätfolge einer chemotherapie -induziert durch sauerstoffexposition

Pneumologie

Volumn 59, Issue 11, 2005, Pages 763-769

  Grahmann, Paul Reinhard ^a   Brauer, M ^a   Huter L ^a   Sayer, H ^a   Neumann, R ^a   Braun, R K ^a,b,c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN;

ARTERIAL GAS; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; EXERCISE; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; NONHODGKIN LYMPHOMA; OXYGEN THERAPY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SPIROMETRY; TONGUE CARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BLOOD GAS ANALYSIS; FEMALE; HODGKIN DISEASE; HUMANS; LUNG TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY INSUFFICIENCY;

EID: 28844483019     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-919069     Document Type: Article

References (18)

1. Klein DS, Wilds PR. Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications. Can Anaesth Soc J 1983; 30 (4): 399-405
2. Putterman C, Polliack A. Late cardiovascular and pulmonary complications of therapy in Hodgkin's disease: report of three unusual cases, with a review of relevant literature. Leuk Lymphoma 1992; 7 (1-2): 109-115
3. Sklar CA, LaQuaglia MP. The long-term complications of chemotherapy in childhood genitourinary tumors. Urol Clin North Am 2000; 27 (3): 563-568,x
4. Bernard GR et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149(3 Pt 1): 818-824
5. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120 (2): 617-624
6. Weiss RB, Muggia FM. Cytotoxic drug-induced pulmonary disease: update 1980. Am J Med 1980; 68 (2): 259-266
7. Beinert T et al. Oxidative pulmonary stress in cytoreductive therapy. Pneumologie 2000; 54 (5): 201-211
8. Cersosimo RJ, Matthews SJ, Hong WK. Bleomycin pneumonitis potentiated by oxygen administration. Drug Intell Clin Pharm 1985; 19(12): 921-923
9. Schaaf W et al. Postoperatives Adult Respiratory Distress Syndrom als mögliche Folge einer sieben Jahre zurückliegenden Bleomycintherapie. Anästh Intensivmed 2003; 44: 436-440
10. Mertens AC et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002; 95 (11): 2431-2441
11. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160 (4): 1347-1352
12. Grahmann PR, Kroegel C. Pulmonale Arzneimittel-Nebenwirkungen. Arzneimitteltherapie 2000; 18 (11): 337-348
13. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991; 65(2): 81-94
14. Kanofsky JR. Singlet oxygen production by bleomycin. A comparison with heme-containing compounds. J Biol Chem 1986; 261 (29): 13546-13550
15. O'Driscoll BR et al. Late carmustine lung fibrosis. Age at treatment may influence severity and survival. Chest 1995; 107 (5): 1355-1357
16. Slosman DO et al. Bleomycin primes monocytes-macrophages for superoxide production. Eur Respir J 1990; 3 (7): 772-778
17. Scheule RK et al. Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am J Physiol 1992; 262 (4 Pt 1): L386-L391
18. Cosset JM et al. Pulmonary toxicity of antimitotic agent-radiotherapy combination. Therapie 1986; 41 (4): 293-296